Sign In

Credits Offered

  • Continuing Medical Education (CME): 9.00 AMA PRA Category 1 Credits™
  • Maintenance of Certification (MOC): 9.00 MOC Points

Accreditation and Designation Statements

Continuing Medical Education (CME)

The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AASLD designates this live activity for a maximum of 9.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 9.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

CME Credits

Physicians and other health care professionals seeking 9.00 AMA PRA Category 1 Credits™ for this live continuing medical education activity must complete an evaluation by Tuesday, April 23, 2019. A link to the CME and MOC evaluation will be emailed to attendees after the conference.

ABIM MOC Points

Physicians seeking ABIM and/or ABP MOC points must complete the CME and MOC evaluation by Tuesday, April 23, 2019. Requests for MOC after this date will not be honored. The MOC evaluation is included in the CME evaluation.

MOC Points will be reported to the ABIM and ABP by the end of April 2019 for attendees who successfully complete the MOC evaluation.

Needs Statement

The Emerging Trends Conference will provide the opportunity for attendees to learn more about and improve upon their selection of precise therapy for patients with hepatocellular carcinoma. Also, attendees will increase their knowledge regarding design, implementation and participation in HCC clinical trials with an enhanced ability to assess the efficacy of treatment using a variety of response criteria.

Learning Objectives

  • Review novel strategies for biomarker based clinical trial designs and articulate new approaches including the role of tumor biopsies and circulating cell-free based assays in guiding therapeutic decision-making.
  • Understand recent advances in integrated molecular classification of HCC and their application to improved treatment of HCC.
  • Review recently approved molecular therapies and anticipated novel immune-based, cellular, and oncolytic virus therapies for HCC and effectively manage the common side effects of these therapies.

Target Audience

  • Hepatologists
  • Oncologist
  • Radiologist
  • Nurses
  • Nurse Practitioners
  • Pharmacists
  • Physician Assistants
  • Transplant Coordinators
  • Surgeons
  • Fellows/Trainees
  • Government/Regulatory Representatives
  • Industry

This activity was planned in the context of the following ACGME/IOM/IPEC competencies:

  • Patient Care and Procedural Skills
  • Medical Knowledge Practice-based Learning and Improvement
  • Systems-based Practice
  • Provide Patient-centered Care
  • Work in Interdisciplinary Teams
  • Roles/Responsibilities Interprofessional Communication
  • Apply Quality Improvement
  • Teams and Teamwork Utilize Informatics